Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) EBT Margin (2021 - 2023)

Senti Biosciences has reported EBT Margin over the past 3 years, most recently at 12808.58% for Q3 2023.

  • For Q3 2023, EBT Margin fell 1187151.0% year-over-year to 12808.58%; the TTM value through Jun 2024 reached 26821.01%, down 2505724.0%, while the annual FY2025 figure was 308418.18%, N/A changed from the prior year.
  • EBT Margin for Q3 2023 was 12808.58% at Senti Biosciences, down from 2095.2% in the prior quarter.
  • Over five years, EBT Margin peaked at 8202.09% in Q4 2022 and troughed at 12808.58% in Q3 2023.
  • A 3-year average of 1442.46% and a median of 1072.89% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: soared 868849bps in 2022 and later tumbled -1187151bps in 2023.
  • Year by year, EBT Margin stood at 486.39% in 2021, then surged by 1786bps to 8202.09% in 2022, then crashed by -256bps to 12808.58% in 2023.
  • Business Quant data shows EBT Margin for SNTI at 12808.58% in Q3 2023, 2095.2% in Q2 2023, and 1081.1% in Q1 2023.